Latest Conference Articles

Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer

Botensilimab in combination with balstilimab induced durable responses in patients with resistant/refractory ovarian cancer.

Lenvatinib Plus Pembrolizumab Produces Deep, Sustained Responses in Advanced Endometrial Cancer

The combination of lenvatinib plus pembrolizumab produced deep, durable tumor responses in both all-comer and mismatch repair–proficient (pMRR) populations of patients with advanced endometrial cancer, according to data from the phase 3 Study 309/KEYNOTE-775 trial.

Toripalimab Plus Bevacizumab/Chemotherapy Generates Responses in Refractory, Recurrent, or Metastatic Cervical Cancer

The combination of toripalimab, bevacizumab, and platinum-based chemotherapy elicited responses in patients with refractory, recurrent or metastatic cervical cancer.

Niraparib Maintenance Does Not Produce Long-term OS Benefit in Recurrent Ovarian Cancer

Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.

Tolerability Hinders Adavosertib Activity in Recurrent or Persistent Uterine Serous Carcinoma

Treatment with the oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated in patients with recurrent or persistent uterine serous carcinoma who previously received platinum-based chemotherapy.

Durvalumab Plus Tremelimumab and Hypofractionated Radiotherapy Shows Early Promise in Gynecologic Cancers

The combination of durvalumab, tremelimumab, and hypofractionated radiotherapy demonstrated early tolerability in patients with gynecologic malignancies and elicited objective responses in those with PD-L1–high tumors.

Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer

Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.

Dr Matulonis on Second-line Maintenance Therapy With Niraparib in Ovarian Cancer

Ursula A. Matulonis, MD, discusses final overall survival results from the phase 3 NOVA trial in patients with ovarian cancer.

Carolina Frailty Index Score Shows Utility in Ovarian Cancer Setting

Women with ovarian cancer may be effectively assessed for frailty status via the Carolina Frailty Index Score.

Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer

The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.

Post-Hoc Analysis Shows PFS Benefit of Maintenance Niraparib Not Affected by Dose Modifications in Ovarian Cancer

The use of an individualized starting dose and dose modifications due to treatment-emergent adverse effects did not impact the efficacy of maintenance niraparib in patients with newly diagnosed ovarian cancer, irrespective of BRCA mutation status.

Neoadjuvant Durvalumab/Tremelimumab Plus Chemo Meets PFS End Point in Advanced Ovarian Cancer  

Neoadjuvant treatment with the combination of durvalumab plus tremelimumab and chemotherapy elicited a promising 12-month progression-free survival rate in patients with advanced-stage ovarian cancer.

Similar Total Scores Are Observed With GCLQ and LELSQ in Assessing Patients With Endometrial Cancer for Lymphedema

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed moderate to substantial agreement across different cutoff points.

Long-Term HRQOL Remains Unimpaired With HIPEC Plus Cytoreductive Surgery in Newly Diagnosed Ovarian Cancer

Administration of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery did not have a negative impact on health-related quality of life compared with cytoreductive surgery alone in patients with newly diagnosed ovarian cancer, according to findings from a phase 2 trial.

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

Although the immune system plays a vital role in attacking tumor cells, the immune mechanisms vary from tumor to tumor, and factors in the tumor microenvironment can reduce the effectiveness of the body’s immune response.

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.

ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

Metronomic Chemotherapy Represents Late Treatment Option for Some Patients With Metastatic Breast Cancer

Hyman B. Muss, MD, discusses the potential benefits of metronomic chemotherapy and which patients with metastatic breast cancer could be candidates, as well as how to approach end-of-life conversations and decisions for patients.

Dr. Carey on the Response-Guided Therapy in HER2+ Breast Cancer

Lisa A. Carey MD, ScM, FASCO, discusses the use of response-guided therapy in HER2-positive breast cancer.

Dr. Borgen on the Importance of Addressing Opioid Use in Breast Cancer Care

Patrick I. Borgen, MD, discusses on the importance of addressing the opioid epidemic through the lens of breast cancer care.

Real-World Outcomes With Sacituzumab Govitecan Match ASCENT in Single-Center Study

In a single-center study, investigators assessed real-world outcomes in patients with metastatic metastatic triple-negative breast cancer treated with the antibody-drug conjugate sacituzumab govitecan-hziy.

Miami Breast Keynotes Highlight the Call to Action for Advocacy Efforts in Breast Cancer

Lindsay Avner Kaplan and Nancy G. Brinker, the keynote speakers of the 40th Annual Miami Breast Cancer Conference, discuss the need to confront social determinants of health for patients and drive the public conversation and interpretation of personal and clinical stories in health care.

Treatment in HR+ Early Breast Cancer May be Best Guided by Risk of Recurrence

After settling the debate of which patients with early-stage, hormone receptor–positive breast cancer require chemotherapy in addition to endocrine therapy, investigators have set their sights on determining whether ovarian function suppression can deliver the same effects of chemotherapy and when to recommend abemaciclib and olaparib.

SERMS, SERDS, and PROTEC Are Poised to Shake Up Treatments for ER+ Breast Cancer

Novel selective estrogen receptor modulators, selective estrogen receptor degraders, and proteolysis-targeting chimera inhibitors have demonstrated early efficacy for patients with breast cancer who experience disease progression following CDK4/6 inhibitor treatment.

Progress in Treating Brain Metastases in Breast Cancer Puts Multidisciplinary Approaches Into Focus

Brain metastases are a common complication in patients with breast cancer, and although systemic therapies for patients with HER2-positive disease have displayed promise in penetration of the blood-brain barrier, work remains for subsets of patients with central nervous system metastases.

Dr. Chagpar on Financial Toxicity and Disparities in Breast Cancer

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the unmet needs regarding financial toxicities for patients with breast cancer.

Artificial Intelligence, MRI, and Interdisciplinary Collaboration Topics Draw Radiologists, Surgeons to Miami

The growth of artificial intelligence allows physicians to see tumors in unprecedented ways.

Dr. Chmura on the Management of Oligometastatic Breast Cancer

Steven J. Chmura, MD, PhD, discusses the current management strategies for oligometastatic breast cancer.

Dr. Kalinsky on the Evolving Treatment Landscape and Sequencing ADCs in TNBC

Kevin Kalinsky, MD, MS, discusses the evolving treatment landscape for patients with triple-negative breast cancer and how to best sequence antibody-drug conjugates within this population.

I-SPY 2 Framework Could Represent the Future of Drug Development in Breast Cancer

By moving away from adjuvant- to neoadjuvant-based protocols, such as I-SPY, investigators may be better able to develop effective treatments for patients in less time by refining the understanding of who will benefit from therapy, enabling strategies with multiple pathway targets, and testing approaches earlier in the disease course.